Predict your next investment

Venture Capital
mbventures.com

See what CB Insights has to offer

Investments

90

Portfolio Exits

14

Funds

3

About MB Venture Partners

MB Venture Partners is a stage agnostic venture capital firm. Generally, the firm seeks to invest in seed and early stage financing but will selectively look at later stage opportunities. MB Venture Partners' primarily invests in biotech and medical devices.

MB Venture Partners Headquarter Location

17 W Pontotoc Avenue Suite 101

Memphis, Tennessee, 38103,

United States

901-322-0330

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing MB Venture Partners

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find MB Venture Partners in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest MB Venture Partners News

Memphis conference to feature 22 medical device startups

Oct 21, 2015

Michael Sheffield Senior Staff writerMemphis Business Journal Michael Sheffield Senior Staff writerMemphis Business Journal Gary Stevenson, principal of local venture capital firm MB Venture Partners, moderates… more Alan Howell | MBJ From Nov. 3-4, the 13th edition of the Musculoskeletal New Ventures Conference at the FedEx Institute of Technology will showcase 22 promising medical device startups. But the event is also going to address two of the most important issues for medical device startups, raising capital and the regulatory environment. Gary Stevenson, principal of local venture capital firm MB Venture Partners, moderates… more Alan Howell | MBJ Gary Stevenson , managing partner of MB Venture Partners, the conference’s long time host, said the panel discussions will cover the complicated environment companies face for product approval from the U.S. Food & Drug Administration and the decline in capital invested in medical device companies over the last five years. “It’s probably at historic lows,” Stevenson said of capital investment. “Biotech has been hot, but there’s no tax on them. Corporate investors have had to fill in the gaps to some extent that us venture capital firms have left.” Stevenson says between more strict FDA guidelines for product approval, the 2.3 percent excise tax on medical devices, and issues with reimbursements for new devices, major device industry players like Medtronic are waiting longer to acquire new technology. “They’re more excited about technologies that have proven themselves through sales,” Stevenson said. “In 2008, the spine industry was very frothy and companies were making acquisitions of companies that hadn’t been approved yet.” Stevenson says one thing he hopes the startups attending the conference learn is the importance of building a business over looking to be acquired by a larger corporation. Meanwhile corporations like Medtronic and Wright Medical have completed mergers with Covidien and Tornier N.V., respectively. Medtronic moved its headquarters to Ireland, where Covidien is based, a move that has been widely seen as a way to avoid the excise tax. “We tell every company we’ve invested in to keep their heads down, build a business and make sure it’s self-sustainable so you’re not relying on anyone to bail you out,” he says. The big companies have taken their eyes off the ball of acquisition of smaller companies. We hope they get over these distractions and turn their attention back to innovation.” Michael Sheffield covers bioscience and biotechnology; manufacturing; tourism and hospitality; and sports business. Contact him at msheffield@bizjournals.com . Industries

MB Venture Partners Investments

90 Investments

MB Venture Partners has made 90 investments. Their latest investment was in Cast21 as part of their Unattributed VC on August 8, 2021.

CBI Logo

MB Venture Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/13/2021

Unattributed VC

Cast21

$0.4M

No

1

7/6/2021

Unattributed VC

CrossRoads Extremity Systems

$3.74M

No

1

12/23/2019

Series B

Lineus Medical

$1.25M

No

2

11/1/2018

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

6/15/2018

Series A - III

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/13/2021

7/6/2021

12/23/2019

11/1/2018

6/15/2018

Round

Unattributed VC

Unattributed VC

Series B

Unattributed VC

Series A - III

Company

Cast21

CrossRoads Extremity Systems

Lineus Medical

Subscribe to see more

Subscribe to see more

Amount

$0.4M

$3.74M

$1.25M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

2

10

10

MB Venture Partners Portfolio Exits

14 Portfolio Exits

MB Venture Partners has 14 portfolio exits. Their latest portfolio exit was Statera Spine on August 27, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/27/2020

Acquired

3

9/24/2018

Acquired

1

1/4/2018

Acquired

1

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/27/2020

9/24/2018

1/4/2018

00/00/0000

00/00/0000

Exit

Acquired

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

1

1

10

10

MB Venture Partners Fund History

3 Fund Histories

MB Venture Partners has 3 funds, including Memphis Biomed Ventures III LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

11/16/2011

Memphis Biomed Ventures III LP

Multi-Stage Venture Capital

$22M

1

10/2/2006

Memphis Biomed Ventures II

Subscribe to see more

$99M

10

10/1/2002

Memphis Biomed Ventures I LP

Subscribe to see more

$99M

10

Closing Date

11/16/2011

10/2/2006

10/1/2002

Fund

Memphis Biomed Ventures III LP

Memphis Biomed Ventures II

Memphis Biomed Ventures I LP

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Amount

$22M

$99M

$99M

Sources

1

10

10

MB Venture Partners Team

2 Team Members

MB Venture Partners has 2 team members, including current Founder, Managing Partner, Gary D. Stevenson.

Name

Work History

Title

Status

Gary D. Stevenson

Founder, Managing Partner

Current

J.R. Hyde

General Partner

Former

Name

Gary D. Stevenson

J.R. Hyde

Work History

Title

Founder, Managing Partner

General Partner

Status

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.